5 Healthcare Stocks to Buy According to Tiger Cub Chase Coleman

Page 1 of 5

In this article, we discuss 5 healthcare stocks to buy according to Tiger Cub Chase Coleman. If you want our detailed analysis of these stocks, go directly to 10 Healthcare Stocks to Buy According to Tiger Cub Chase Coleman

5. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Tiger Global Management’s Stake Value: $28,106,000

Percentage of Tiger Global Management’s 13F Portfolio: 0.05%

Number of Hedge Fund Holders: 32

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), a biotech company engaged in genetic engineering to produce bacteria with industrial applications, is one of the best healthcare stocks to buy according to Tiger Cub Chase Coleman. Coleman, via Tiger Global Management, holds a $28.1 million stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), which accounts for 0.05% of the firm’s total Q3 securities. 

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) published on November 15 its Q3 results. The company posted a loss per share of $0.08, missing estimates by $0.05. Revenue for the quarter equaled $77.61 million, exceeding estimates by $31.61 million. 

Jefferies analyst Laurence Alexander on November 29 initiated coverage of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) with a Buy rating and a $16 price target. With $1.7 billion cash on hand, the analyst projects Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) to be able to leverage secular trends in favor of synthetic biology to grow from $221 million in sales in 2021 to $1.1 billion in 2025 and $4.5 billion in 2030. He expects Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) to monetize the value of its programs through a mix of royalties, license payments, and equity share.

In the third quarter database of 867 elite hedge funds maintained by Insider Monkey, 32 funds reported owning stakes in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), worth $5.69 billion. 

Page 1 of 5